Lazard’s Healthcare Group completed its third in-depth study of global healthcare industry leaders, surveying 184 C-level executives and 37 investors across three sectors: Biopharmaceuticals; Medical Devices and Diagnostics; and Healthcare Services.
Lazard’s third annual Global Healthcare Industry Leaders Study differs from prior years’ studies, which focused on the broad strategic priorities for the healthcare sector. In contrast, this year’s study focuses on the matters at hand faced by industry leaders: pandemic-related concerns, challenges, and expectations – both for the near term and longer term.
